期刊
MOLECULES
卷 26, 期 5, 页码 -出版社
MDPI
DOI: 10.3390/molecules26051253
关键词
LHRH receptor; targeted therapy; bladder cancer; radioligand binding assay; immunohistochemistry; Western Blot; RT-PCR
资金
- Ministry for Innovation and Technology in Hungary [GINOP-2.3.2-15-2016-00043, TKP2020-IKA-04]
- European Union
- European Regional Development Fund
This study investigates the expression of LHRH and LHRH-R-I in transitional cell carcinoma (TCC) type of human bladder cancer, finding high incidence of expression of both in the samples examined. Positive immunostaining for LHRH-R-I with different expression intensity was found in all samples, showing a negative correlation with TCC grade.
Bladder cancer (BC) is the tenth most frequently detected cancer in both sexes. Type-I luteinizing hormone-releasing hormone (LHRH) receptor (LHRH-R-I) is expressed not only in the pituitary, but also in several types of cancer disease. There are few data about LHRH-R-I expression in human BC. This study aimed to investigate the expression of LHRH and LHRH-R-I in the transitional cell carcinoma (TCC) type of human BC. RNA was extracted from 24 human bladder tumor specimens and three BC cell lines. RT-PCR was performed to detect mRNA for LHRH and LHRH-R-I. The protein of LHRH-R-I was further studied by immunohistochemistry (IHC), ligand competition assay, and Western Blot. PCR products of LHRH were found in 19 of 24 (79%) specimens and mRNA of LHRH-R-I was detected in 20 of 24 specimens (83%). Positive immunostaining for LHRH-R-I with different expression intensity was found in all samples examined, showing negative correlation with TCC grade. Radioligand binding studies also showed the presence of specific LHRH-R-I and high affinity binding of LHRH analogs. The high incidence of LHRH-R in BC suggests that it could serve as a molecular target for therapy of human BC with cytotoxic LHRH analogs or modern powerful antagonistic analogs of LHRH.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据